Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone in Adults =65 Years of Age.

Trial Profile

Phase III Lot Consistency, Immunogenicity and Safety Study of Three Lots of Fluzone High Dose Vaccine Compared With One Lot of Standard Fluzone in Adults =65 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2014

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 25 Aug 2009 Actual patient number changed from 3837 to 3876 as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Results published in the Journal of Infectious Diseases.
    • 26 Oct 2008 Results have been reported at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual meeting, according to a Sanofi Pasteur media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top